Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group
- PMID: 7844872
Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group
Abstract
Objective: To assess the safety and efficacy of optic nerve decompression surgery compared with careful follow-up alone in patients with nonarteritic anterior ischemic optic neuropathy (NAION).
Design: The Ischemic Optic Neuropathy Decompression Trial (IONDT) is a randomized, single-masked, multicenter trial.
Setting: Twenty-five US clinical centers.
Participants: The IONDT ceased recruitment on October 20, 1994, on the recommendation of its Data and Safety Monitoring Committee. The preliminary results presented herein are based on data as of September 8, 1994, from 244 patients with NAION and visual acuity of 20/64 or worse. One hundred twenty-five patients had been randomized to careful follow-up, and 119 had been randomized to surgery, with 91 and 95, respectively, having completed 6 months of follow-up.
Intervention: Patients in the surgery group received optic nerve decompression surgery and follow-up ophthalmologic examinations; those in the careful follow-up group received ophthalmologic examinations at the same times as the surgery group.
Main outcome measures: Gain or loss of three or more lines of visual acuity on the New York Lighthouse chart at 6 months after randomization, as measured by a technician masked to treatment assignment.
Results: Patients assigned to surgery did no better when compared with patients assigned to careful follow-up regarding improved visual acuity of three or more lines at 6 months: 32.6% of the surgery group improved compared with 42.7% of the careful follow-up group. The odds ratio (OR) for three or more lines better, adjusted for baseline visual acuity and diabetes, was 0.74 (95% confidence interval [CI], 0.39 to 1.38). Patients receiving surgery had a significantly greater risk of losing three or more lines of vision at 6 months: 23.9% in the surgery group worsened compared with 12.4% in the careful follow-up group. The 6-month adjusted OR for three or more lines worse was 1.96 (95% CI, 0.87 to 4.41). No difference in treatment effect was observed between patients with progressive NAION and all others.
Conclusion: Results from the IONDT indicate that optic nerve decompression surgery for NAION is not effective, may be harmful, and should be abandoned. The spontaneous improvement rate is better than previously reported.
Comment in
-
Ischemic optic neuropathy decompression trial.JAMA. 1995 Aug 23-30;274(8):612. JAMA. 1995. PMID: 7637140 No abstract available.
-
Clarifying the treatment of nonarteritic anterior ischemic optic neuropathy.JAMA. 1995 Feb 22;273(8):666-7. JAMA. 1995. PMID: 7844879 No abstract available.
Similar articles
-
Ischemic Optic Neuropathy Decompression Trial: twenty-four-month update.Arch Ophthalmol. 2000 Jun;118(6):793-8. Arch Ophthalmol. 2000. PMID: 10865316 Clinical Trial.
-
The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study.Am J Ophthalmol. 2002 Sep;134(3):317-28. doi: 10.1016/s0002-9394(02)01639-2. Am J Ophthalmol. 2002. PMID: 12208242 Clinical Trial.
-
Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial.Arch Ophthalmol. 1996 Nov;114(11):1366-74. doi: 10.1001/archopht.1996.01100140566007. Arch Ophthalmol. 1996. PMID: 8906027 Clinical Trial.
-
[Nonarteritic ischemic optic neuropathy animal model and its treatment applications].Nippon Ganka Gakkai Zasshi. 2014 Apr;118(4):331-61. Nippon Ganka Gakkai Zasshi. 2014. PMID: 24864434 Review. Japanese.
-
New Treatments for Nonarteritic Anterior Ischemic Optic Neuropathy.Neurol Clin. 2017 Feb;35(1):1-15. doi: 10.1016/j.ncl.2016.08.003. Neurol Clin. 2017. PMID: 27886887 Review.
Cited by
-
Nonarteritic anterior ischemic optic neuropathy.J Clin Hypertens (Greenwich). 2005 Feb;7(2):130-3. doi: 10.1111/j.1524-6175.2005.04095.x. J Clin Hypertens (Greenwich). 2005. PMID: 15722660 Free PMC article. Review.
-
Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial.Graefes Arch Clin Exp Ophthalmol. 2006 May;244(5):551-8. doi: 10.1007/s00417-005-0102-8. Epub 2005 Sep 8. Graefes Arch Clin Exp Ophthalmol. 2006. PMID: 16151785 Clinical Trial.
-
Efficacy of intravitreal ranibizumab injection in acute nonarteritic ischemic optic neuropathy: a long-term follow up.Open Ophthalmol J. 2013 Sep 30;7:58-62. doi: 10.2174/1874364101307010058. eCollection 2013. Open Ophthalmol J. 2013. PMID: 24133556 Free PMC article.
-
Intravitreal triamcinolone injections in non-arteritic anterior ischemic optic neuropathy.Graefes Arch Clin Exp Ophthalmol. 2014 Feb;252(2):339-45. doi: 10.1007/s00417-013-2499-9. Epub 2013 Nov 1. Graefes Arch Clin Exp Ophthalmol. 2014. PMID: 24178807 Clinical Trial.
-
A new characterization for nonarteritic anterior ischemic optic neuropathy.Int J Clin Exp Med. 2015 Oct 15;8(10):18681-8. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26770482 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical